Skip to content

From the American College of Rheumatology

Rheumatology for Primary Care
  • Symptoms
    • Fever
    • Joint Pain
    • Muscle Pain and/or Weakness
    • Rashes
    • Raynaud’s Phenomenon
  • Diseases
    • ANCA-Associated Vasculitis
    • Behcet’s Syndrome
    • Crystalline Arthropathies
    • Drug and Medication-Induced Rheumatic Diseases
    • Giant Cell Arteritis
    • Henoch-Schönlein Purpura
    • IgG4-Related Disease
    • Juvenile Dermatomyositis
    • Juvenile Idiopathic Arthritis
    • Kawasaki Disease
    • Mixed Connective Tissue Disease
    • Multisystem Inflammatory Syndrome in Children
    • Myositis
    • Polyarteritis Nodosa
    • Polymyalgia Rheumatica
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjogren’s Disease
    • Spondyloarthritis
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
  • Case Studies
    • ANCA-Associated Vasculitis
    • Behcet’s Syndrome
    • Crystalline Arthropathies
    • Giant Cell Arteritis
    • Henoch-Schönlein Purpura
    • IgG4-Related Disease
    • Juvenile Dermatomyositis
    • Juvenile Inflammatory Arthritis
    • Kawasaki Disease
    • Mixed Connective Tissue Disease
    • Myositis
    • Pediatric Fevers
    • Polyarteritis Nodosa
    • Polymalgia Rheumatica
    • Raynaud’s Phenomenon
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sicca/Sjogren’s Disease
    • Spondyloarthritis
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
  • Labs
  • Meds
    • Commonly Used Rheumatology Meds
    • Treatment Considerations
    • Addressing Patient Fears About Rheumatology Medications
    • Medications by Diseases
  • Resources
    • Resources
    • Vaccination Considerations – Pediatrics
    • Vaccination Considerations – Adults
    • Glossary of Terms
    • ACR Clinical Guidelines
    • ACR Education Center
    • Rheumatology Provider Directory

Treatment Considerations

Home » Meds » Treatment Considerations
Treatment ConsiderationsPrimary Care2024-10-21T22:13:47+00:00
  • Drug Toxicities

  • Perioperative Concerns

  • Drug Toxicities

What are major side effect profiles that I should be aware of?
(The following is not an inclusive list. Additionally, many of these side effects occur uncommonly, except when noted.)

Neuro-Psychiatric

  • Apremilast, belimumab, and brodalumab – worsening depression and suicidal ideation
  • Steroids can cause mood disorders (common)
  • TNF-alpha inhibitors can cause demyelinating disorders

Ophthalmologic

  • Hydroxychloroquine – need to see ophthalmology annually while on this medication given retinal toxicity
  • Steroids – can cause glaucoma and cataracts

Cardiovascular/Thrombotic

  • JAK inhibitors have a black box warning for thrombosis and cardiovascular disease
  • IL-6 inhibitors can increase lipids – both LDL and HDL (common)
  • Steroids and NSAIDs can increase risk of CVD, HTN
  • Hydroxychloroquine can rarely cause cardiomyopathy

Pulmonology

  • Methotrexate can causes interstitial pneumonitis
  • Abatacept can worsen COPD exacerbations

Hepatic/Renal Toxicity

  • Hepatotoxic – methotrexate, leflunomide, NSAIDs, azathioprine, IL-6 inhibitors (common)
  • Several medications may affect the kidneys, or are renally dosed (common)

Gastrointestinal

  • IL-6 inhibitors and JAK inhibitors gastrointestinal perforation
  • Steroids can cause PUD (common)
  • NSAIDs can use PUD and gastritis; COX-2 inhibitors have better tolerated GI side effects (common)
  • IL-17 inhibitors can worsen or cause inflammatory bowel disease

Infectious

  • Most of these medications need to be held when somebody has an acute infection or is on antibiotics. An exception to this rule is hydroxychloroquine, which can be continued.
  • Consider these specific infections:
    • Hepatitis B reactivation – TNF-alpha inhibitors, rituximab
    • Latent tuberculosis reactivation – TNF-alpha inhibitors
    • Progressive multifocal leukoencephalopathy (PML) – rituximab
    • Herpes zoster – belimumab, JAK inhibitors
    • Pneumocystis pneumonia – steroids (consider PJP prophylaxis when indicated)
    • Meningococcemia – eculizimab

Hematology/Oncology

  • Cytopenia: Rituximab, methotrexate, sulfasalazine, leflunomide, mycophenolate, azathioprine, IL-1 inhibitors
  • Malignancy (particularly skin cancers): Methotrexate, azathioprine, mycophenolate, TNF-alpha inhibitors, cyclophosphamide

Endocrine

  • Steroids can cause hyperglycemia (diabetes), osteoporosis, and adrenal insufficiency; consider calcium/vitamin D supplementation and screening DEXA (common)

Teratogenic

View ACR Reproductive Health Guideline.

  • Cyclophosphamide, leflunomide, methotrexate, mycophenolate, thalidomide
  • Perioperative Concerns

Should you schedule elective surgeries for patients on rheumatology medications?

  • Hold most medications one dosing interval prior to surgery.
  • Hold for 2 weeks until wound healing.
  • Look at the guidelines for specific medications.

Related Links

Drug and Medication-Induced Rheumatic Disease Information

 

ACR Reproductive Health Guideline

 

ACR Perioperative Management Guideline

We Want Your Input

Find what you needed? We would love your feedback so that we can ensure the site meets the needs of primary care providers.

Give Feedback

American College of Rheumatology Information

About ACR

ACR Contacts

Authors

This product was funded by a medical grant from Pfizer. The content was written by a physician work group. See Authors

© Copyright American College of Rheumatology 2025 | All rights reserved | See ACR Policies

Page load link
Go to Top